Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Mi2000 TICI - Post-market Implantation Study (TUPIS)

11. November 2026 aktualisiert von: MED-EL Elektromedizinische Geräte GmbH

This Post-Market Clinical Follow-up (PMCF) investigation aims to further collect evidence on safety and performance of the Mi2000 TICI. This PMCF investigation will prospectively collect clinical data from the use of the Mi2000 TICI and related devices.

This PMCF investigation is performed on a cochlear implant system newly introduced to the market, which was previously studied in two pre-market clinical investigations. The purpose of the current clinical investigation is to collect further evidence by collecting additional clinical data on the use of the Mi2000 TICI.

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

22

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Liège, Belgien, 4000
        • Noch keine Rekrutierung
        • Centre Hospitalier Universitaire de Liège, Department ORL
        • Kontakt:
          • Philippe Lefebvre, Dr.med.
    • Belgium
      • Antwerp, Belgium, Belgien, 2650
        • Noch keine Rekrutierung
        • UZA Antwerpen
        • Kontakt:
          • Vincent van Rompaey, Prof. Dr.
      • Würzburg, Deutschland
        • Noch keine Rekrutierung
        • Universitätsklinikum Würzburg
        • Kontakt:
          • Kristen Rak, Prof. Dr.
    • Bavaria
      • München, Bavaria, Deutschland, 81377
        • Rekrutierung
        • Klinikum der Universität München, Campus Großhadern
        • Kontakt:
          • Joachim Müller, Dr.med.
    • Poland
      • Nadarzyn, Poland, Polen, 05-830
        • Noch keine Rekrutierung
        • The Institute of Physiology and Pathology of Hearing
        • Kontakt:
          • Piotr Skarzynski, Prof. Dr.

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Minimum age of eighteen (18) years at time of enrolment
  • Bilateral sensorineural hearing loss with no or limited benefit from a hearing aid (>70 dB HL PTA4(500, 1000, 2000, 4000Hz))
  • Post-lingual onset of deafness
  • No or limited benefit from hearing aids for less than 10 years and an expected benefit from cochlear implantation
  • A maximum score of 50% on a word test in the language of the test center in the ear to be implanted in the best aided condition
  • Fluency in the test language with excellent proficiency, as appropriate to perform speech testing
  • Functional auditory nerve
  • General health condition, psychological and emotional condition deemed compatible with the treatment and tests performed in this study
  • Pre-operative assessment according to the local professional standards
  • Candidate is highly motivated and has realistic expectations about the expected benefit of the implant and shall understand the importance of returning to the implant center for regular speech processor programming, assessment sessions and training
  • Realistic expectations, as deemed appropriate by the implanting surgeon/implant board
  • Signed and dated informed consent before the start of any study-specific procedure

Exclusion Criteria:

  • Lack of compliance with any inclusion criterion

  • Previously having received an implant on the location chosen for placing the cochlear implant

  • Having received a hearing implant from another manufacturer than MED-EL on the contralateral ear

  • Pre-existing condition known to necessitate MRI scans after implantation of the Mi2000 TICI

  • Women being pregnant or nursing

  • The individual is known to be intolerant of the materials used in the implant or other required accessories

  • Absence of cochlear development

  • The cause of deafness is non-functionality of the auditory nerve and/or the upper auditory pathway

  • Medical contra-indications to middle ear and/or inner ear surgery, and/or anesthesia

  • External or middle ear infections are present

  • The tympanic membrane is perforated in the ear to be implanted

  • Anatomic abnormalities are present that would prevent appropriate placement of the stimulator housing in the bone of the skull, or prevent placement of the chosen electrode array into the cochlea (including ossification of the cochlea)

  • The psychological status of the individual is unstable

  • The individual has unrealistic expectations

  • Acute cholesteatoma

  • History of vestibular schwannoma

  • Unstable Meniere's disease

  • Auditory Neuropathy

  • Epilepsy not responding to treatment

  • Permanent inability and/or unwillingness to participation in post-operative care and rehabilitation

  • Known intellectual disability and/or psychological diseases

  • Participation in other pharmacological clinical trials within four weeks prior to enrolment

  • Anything that, in the opinion of the Investigator, would

    • place the subject at increased risk
    • preclude the subject's full compliance with or completion of the study

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: TICI recipients

Participants in this clinical investigation will be implanted with an Mi2000 TICI totally cochlear implant

Participants in this clinical investigation will receive a totally implantable cochlear implant.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Word Test in Quiet
Zeitfenster: Pre-op to 6 months after first fitting

Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes

Pre-op to 6 months after first fitting
Sentence Test in Noise
Zeitfenster: Pre-op to 6 months after first fitting

Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes

Pre-op to 6 months after first fitting

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Health Utility Index Mark 3 (HUI3)
Zeitfenster: Pre-op to 6 months after first fitting

Health utility scale:

1.00: Perfect health. 0.00: Death. Negative values: States worse than death.

Pre-op to 6 months after first fitting
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Zeitfenster: Pre-op to 6 months after first fitting

Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes

Pre-op to 6 months after first fitting
Change in body sound perception
Zeitfenster: through study completion, an average of 12 months after first fitting

Participant reported scale on body sound perception (0 - no disturbance to 10 - very disturbing)

through study completion, an average of 12 months after first fitting
Change in stigma perception
Zeitfenster: through study completion, an average of 12 months after first fitting

Participant reported scale on stigma perception (0 - no stigmatization to 10 - strong stigmatization)

through study completion, an average of 12 months after first fitting
Change in comfort perception
Zeitfenster: through study completion, an average of 12 months after first fitting

Participant reported scale on stigma perception (0 - not comfortable to 10 - very comfortable)

through study completion, an average of 12 months after first fitting

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Word test in quiet
Zeitfenster: through study completion, an average of 12 months after first fitting

Word recognition in quiet, on a scale from 0 to 100% correct, higher scores indicate better outcomes

through study completion, an average of 12 months after first fitting
Sentence Test in Noise
Zeitfenster: through study completion, an average of 12 months after first fitting

Oldenburg Matrix Test, results measured in dB signal-to-noise ratio (SNR) with a range of +30 to -10 dB SNR, lower values indicating better outcomes

through study completion, an average of 12 months after first fitting
Health Utility Index Mark 3 (HUI3)
Zeitfenster: through study completion, an average of 12 months after first fitting

Health utility scale:

1.00: Perfect health. 0.00: Death. Negative values: States worse than death.

through study completion, an average of 12 months after first fitting
Nijmegen Cochlear Implant Questionnaire (NCIQ)
Zeitfenster: through study completion, an average of 12 months after first fitting

Disease specific Quality of Life, overall score is on a scale from 0 to 100, higher numbers indicating better outcomes

through study completion, an average of 12 months after first fitting
Speech, Spatial, Quality of Hearing (SSQ12)
Zeitfenster: through study completion, an average of 12 months after first fitting

Speech, Spatial and Quality of hearing scale from 0 to 10, higher numbers indicating better outcomes

through study completion, an average of 12 months after first fitting
Hearing Implant Sound Quality Index (HISQUI)
Zeitfenster: through study completion, an average of 12 months after first fitting

Sound quality score ranging from 19 (very poor sound quality) to 133 (very good sound quality)

through study completion, an average of 12 months after first fitting
Tinnitus Functional Index (TFI)
Zeitfenster: through study completion, an average of 12 months after first fitting

Tinnitus questionnaire measures the severity and negative impact of tinnitus on a 0 (Not a Problem / Slight Tinnitus) to 100 (Very Big Problem / Very Severe Tinnitus) scale

through study completion, an average of 12 months after first fitting
Audiogram
Zeitfenster: through study completion, an average of 12 months after first fitting

Pure-tone air-conduction hearing thresholds will be measured in each ear. The threshold is the lowest sound level, in decibels hearing level (dB HL), at which the participant responds. The outcome is the threshold at each frequency. Higher thresholds mean poorer hearing; lower thresholds better hearing.

through study completion, an average of 12 months after first fitting

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Studienleiter: Florian Schwarze, MED-EL

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. November 2026

Primärer Abschluss (Geschätzt)

1. Januar 2029

Studienabschluss (Geschätzt)

1. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

15. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Oktober 2026

Zuerst gepostet (Tatsächlich)

27. Oktober 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

12. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

11. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren